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Amiodipbw is a dihyckopyridsne derivative belong- 
ingtothegmlpof -&y;;za bbcldngag~andischar 
slowensetandreiatlvelylengduratlonofactlon 
with minknal effects on cardiac ektrophysiology 
and myocardlal contractility. 
The protective effect of ambdipine was studled 
in isolated blood-perksed feline hearts made gbb- 
ally bchemic for 60 mktes followed by reperfu- 
slon for 60 minutes. Ischemii-indueed alterations 
OfldtV-devdoped preswre and compli- 
anceweremonitored.Inllcontroland7drug- 
treated hearts, amiot@ine pmwhced slgnlltcant de- 
creases in myaeardlai oxygen consumption (6.2 f 
0.4 to 4A f 0.4 ml oxygen/min/lOO g) and coro- 




contracture as retlected by a progressive increase 
in resting left ventrkdar diastolic pressure. The re- 
tlHllOfcantraetilefunetlon,6Olldnutcsi2ft~reper- 
fusion, improved slgn8kantly in the amkdipine- 
treatedgroupcomparedwfthumtrolqandthsre 
wasbettermabltenanee ofthetissue conceWatii 
of Na+, W+ and K+. 
A canke model of regional myocardial ischemia 
(6Ominutes)followedby6hoursofrepetfusion 
was used to assess the cardloprotective effects of 
ambdiplne, 160 */kg, administered 15 minutes 
before repehnh. Infarct size, expressed as a 
~eoftheareaatrisk,wassmallerinthe 
ambdlplne-treated grsup (n = 10) than in the con- 
trolgroup(n= 10)(346*3~%vs46.9f2.8%, 
p = 0.027). Risk region size did not differ between 
groups and both groups were comparable with re- 
z= hemodynamii parametera of heart 
presswe and rate-pressure product. 
Amlkdlplm pre~ented the gradual reductk in cor- 
onarybloodflowobservedinthecontrolgroup. 
From the Dqrtment of Pharmacology, The University of Michigan 
Medical School, Ann Arbor, Michigan. This study was supported by 
Grant HL-19782-10 from the Heart, Lung, and Blood Institute, Na- 
tional Institutes of Health, Bethesda, Maryland; and a grant from 
Pfiir Central Research, United Kingdom. 
Address for reprints: Benedict R. Lucchesi, PhD, MD, Department 
of Pharmacology, M6322 Medical Science Building I, The University 
of Michigan Medical School, Ann Arbor, Michigan 48 109-0626. 
It is eomkded that amlodlpine reduces myocar- 
dii ischemii i- by mechanism(s) that may in- 
volve a reduc&m h myocardiil oxygen demand as 
well as by positively infkencing transmembrane 
Ca*+ fluxes during ischemii and reperksion. 
(Am JCardid 1989;64:101 I-1161) 
C alcium ion (Ca2+) channel entry blockers have found application in the treatment of a variety of cardiovascular disorders.1*2 Amlodipine, [3-ethyl 
Smethyl 2-(2 aminoethoxymethyl) 4-(2 chlorophenyl) 
1 ,Cdihydro 6-methyl 3,5pyridine-dicarboxylate ben- 
zene sulfonate], is a new addition to the dihydropyridine 
class of voltage-dependent Ca2+ channel entry blockers. 
In addition to possessing many of the properties of the 
prototype dihydropyridine, nifedipine, amlodipine dis- 
plays a slow-onset and relatively long duration of ac- 
tion.3-5 Because of the relative selectivity of these agents 
for vascular smooth muscle without significant cardiac 
side effects,6*7 the pharmacologic profile of the dihydro- 
pyridines makes them particularly suitable for the pre- 
vention of myocardial injury in the setting of ischemia 
and reperfusion.*-‘0 
Myocardial ischemia is associated with a loss of Ca2+ 
homeostasis.1i-13 The subsequent increase in free intra- 
cellular Ca2+ is a consequence of ischemic tissue inju- 
ry, 14-i6 and has been shown to be associated with de- 
creased recovery of myocardial contractile function, com- 
promised membrane integrity and a progressive decline 
in cellular adenosine triphosphate (ATP) stores. Previous 
studies in our laboratory and elsewhere have demon- 
strated the efficacy of diltiazem and nifedipine in protect- 
ing the myocardium against irreversible tissue injury in 
the setting of global or regional ischemia followed by 
reperfusion.17-l9 Because of this favorable pharmacologic 
profile it was considered of interest to explore the poten- 
tial of amlodipine to protect the myocardium against the 
development of irreversible cellular injury associated with 
a period of ischemia followed by reperfusion. 
The study was conducted in 2 well-characterized ex- 
perimental models that allowed for the induction of glob- 
al myocardial ischemia (blood-perfused, feline isolated 
heart20) or regional myocardial ischemia (coronary ar- 
tery occlusion, canine heart) followed by reperfusion.21p22 
Pretreatment with amlodipine resulted in an improved 
return of function on reperfusion of the globally ischemic 
heart and a significant reduction in myocardial injury in 
response to regional myocardial ischemia followed by 
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(a) Pre-Ischemic Measurements 
(d) Post-Ischemic Measurements 
Coronary Blood Flow (at LVEDP = 0 nunHg) 
Function &Compliance Curves (LVEDP = O-30 mmBg) 
Paced (150 bpm) 
(b) Pm-Drug or Saline Measurements 
Coronary Blood Flow (at LVBDP = 0 mmHg) 
Heart Rate (intrinsic) 
(c) Post-Drug or Saline Measurements 
LV$2(LV balloon volume was adjusted = LVDP = 120 mmHg) 
Not paced 
reperfusion. Thus, amlodipine may be of potential value 
in instances where myocardial cell viability is jeopardized 
by ischemia or reperfusion, or both. 
MEWODS 
Studies in fedine blood-pehsed isolated heart to de- 
temnins edfats of amlodipine on mechanical and bio- 
cilenlii fllmiod paramotors after gbbai iwiKJmia 
and mmmontai protocok The experi- 
ments were performed in a model of global ischemia 
previously described by Vogel and Lucchesi.20 Hearts 
were obtained from cats (1.5 to 3.0 kg) of either gender, 
anesthetized with sodium pentobarbital(30 mg/kg intra- 
peritoneally) and treated with the anticoagulant sodium 
heparin, 300 U/kg intravenously (i.v.). Blood donor cats 
(3.0 to 6.0 kg) of either gender were anesthetized with 
Dial-Urethane (0.7 ml/kg intraperitoneally) containing 
allobarbital, 100 g/liter; urethane, 400 g/liter; and mon- 
oethylurea, 400 g/liter. Blood donor cats were heparin- 
ized with an initial dose of heparin, 400 U/kg i.v., and 
subsequent hourly doses of 300 U/kg. Tracheotomy of 
donor cats was performed and they were ventilated with 
room air using a Harvard respirator pump with rate and 
tidal volume adjusted to maintain normal arterial blood 
values of pH, ~02 and pCO2, which were measured dur- 
ing the course of each experiment. Catheters were placed 
in the right and left femoral artery and a femoral vein of 
the donor cat to measure arterial blood pressure and for 
connection to the blood perfusion apparatus and venous 
return reservoir. 
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The heart was removed quickly from the donor cat 
and perfused via the aorta with arterial blood drawn from 
the blood donor cat with a bilateral roller pump. Aortic 
perfusion pressure was maintained between 75 and 90 
mm Hg by adjusting the speed of the roller pump which 
delivered blood from the donor cat to the isolated heart. 
The temperature of the blood that perfused the isolated 
heart was maintained at 37OC by passing it through a 
heat exchanger. Coronary venous blood was drained from 
the right ventricle of the isolated heart by cannulation of 
the pulmonary artery and was returned to the donor cat 
via the femoral vein as was the Thebesian drainage from 
the left ventricle which exited from a cannula inserted at 
the apex of the heart. 
A salinefilled latex balloon connected to a pressure 
transducer was placed in the left ventricle by insertion 
through the left atrium and across the mitral valve. Blood 
that passed the aortic valve of the isolated heart and 
collected in the left ventricle was drained via a vent in the 
apex of the heart. The heart was surrounded by a glass 
water jacket maintained at 37OC. The hearts were paced 
electrically by a pair of bipolar platinum wire electrodes 
attached to the right atrium. Before undergoing global 
&hernia, the isolated heart was allowed to equilibrate for 
at least 30 minutes. Heart rate and left ventricular end- 
diastolic pressure (LVEDP) were maintained at 150 
beats/mm and 15 mm Hg (by adjustment of the intra- 
ventricular balloon volume), respectively. 
After equilibration, preischemic measurements of the 
left ventricular mechanical function were obtained by 













(n = 11) 
Amlodipine 
(n = 7) 
156 153 120 120 18.8 18.3 
f8 *9 fl fl fl i l 
141 136 120 1005 16.9 13.8s 






















l Heart rattintrinsic (nonpaced) rate. 
t Ralbn vdume was adjwted so that initial LVDP was approximately 120 mm Hg. 
I * t&Q = myocardial oxygen consumptiin, calculated from the formula: hlV02 = IAs - VO&ols “/d) X CBF(ml/min) Heart Weight(g) 
I 5 p SO.005 between pfe and pestinfusion values (paired f test). CBF = Coronary blood Row; LVDP = left ventricular developed pressure 
generating function (Starling) and compliance curves. 
This was accomplished by measuring left ventricular de- 
veloped pressure (LVDP), left ventricular dP/dT and 
LVEDP on inflation of the intraventricular balloon in 
increments of 0.2 ml over a range of volumes producing 
LVEDPs of 0 to 30 mm Hg. Isolated feline hearts were 
paced electrically during the pre- and postischemic mea- 
surements of mechanical function to minimize the differ- 
ences in contractility due to heart rate.23 The hearts were 
divided randomly into 2 groups: saline and amlodipine- 
treated groups. The dose of amlodipine was based on the 
weight of the blood donor cat. The isolated heart was 
exposed to either amlodipine (150 pg/kg donor cat, dis- 
solved in 5 ml of saline) or saline (5 ml) and administered 
by infusion over a period of 5 minutes into the femoral 
vein of the blood donor cat (Fig. 1). 
The effects of amlodipine on myocardial contractile 
performance and oxygen (02) consumption (MV02) 
were assessed under conditions described in the legend to 
Table I. MV02 was determined by measuring the 02 
content of arterial and venous blood samples, drawn from 
the aortic and pulmonary arterial cannulas, respectively. 
02 content of the blood was determined with the use of a 
Lex-02~Con 02 analyzer (Lexington Instruments, Wal- 
tham, Massachusetts), which was calibrated against 
room air and for ambient barometric and water-vapor 
pressures. Coronary blood flow was measured by collect- 
ing timed samples from the pulmonary arterial cannula in 
a graduated cylinder at 0 mm Hg LVEDP. 
After contractile measurements, isolated hearts were 
made globally ischemic for 60 minutes by turning off the 
roller pump delivering arterial blood to the heart. The 
volume of the intraventricular balloon was set so as to 
produce 15 mm Hg LVEDP immediately before the in- 
duction of global ischemic arrest of the heart. LVEDP 
was allowed to change spontaneously over the course of 
the ischemic period. When subjected to global ischemic 
arrest, the isolated hearts were kept normothermic 
(37OC) by immersion in physiologic saline contained in a 
heated jacketed reservoir. Electrical pacing was diicon- 
tinued during the ischemic period. 
At the end of the 6Ominute period of global &hernia, 
reperfusion was initiated by restoring blood flow to the 
isolated hearts. Poetischemic perfusion was maintained 
for 60 minutes and the coronary blood flow was adjusted 
to a rate that returned perfusion pressure to preischemic 
levels (75 to 90 mm Hg). At the onset of reperfusion, the 
volume in the left ventricular balloon was decreased to 0 
mm Hg LVEDP in order to prevent elevated end-diastol- 
ic pressure from impeding transmural coronary blood 
flow as a result of extravascular compression.24 Hearts 
that developed ventricular fibrillation on reperfusion 
were defibrillated with an injection of 0.05 ml saturated 
KC1 solution (not recirculated) into the aortic cannula 
immediately above the coronary ostia. Isolated hearts 
were not paced on restoring perfusion. Electrical pacing 
at the preischemic rate was maintained, however, during 
the assessment of contractile function in the postischemic 
recovery period. After 60 minutes of reperfusion, post- 
ischemic measurements of coronary blood flow and con- 
tractile function were repeated as described. 
After obtaining postischemic measurements, the iso- 
lated hearts were perfused with 100 ml Krebs solution to 
remove blood from the vascular bed and subsequently 
were removed from the perfusion apparatus. Intact hearts 
from the blood donor cats were excised and served as 
controls because they were not subjected to the damaging 
effects of the ischemic period, but were exposed to the 
same pharmacologic interventions as the isolated blood- 
perfused hearts. The intact hearts were weighed as were 
tissue samples obtained from both hearts. The myocardi- 
al samples were stored in a freezer at -2OOC. 
Tkrue water eonten& Samples of ischemic-reper- 
fused and control (from blood donor cats) nonischemic 
myocardial tissues were blotted, weighed and dried in an 
oven to constant weight. Tissue water content, expressed 
as ml/g dry weight was calculated from the ratio of tissue 
wet and dry weights. 
tissue m The dried tissue samples were 
digested and extracted with HNO3 and trichloroacetic 
acid and diluted with distilled water. Tissue Na+ and K+ 
contents were determined by flame photometry (Instru- 
mentation Laboratories, IL- 143) and tissue Ca*+ content 
was determined by atomic absorption spectrophotometry 
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A SYMPOSIUM: PHARMACOLOGY AND TNERAPEUTIC CONSIDERATIONS OF AMLODIPINE 
90 min LCX Occlusion 6 Hours Reperfusion 
15 min i.v. infusion of 
Amlodipine(l50Fg/kg) or Saline 
FlGuRE2.ProtoadforuK!sludyofmkdphaoncnirw,~ isdnmlard 
ti+ = cddm~ ion; H.R. = heal w i.v. = inlrm 
lwpehahinCvr.aP.=bbod~ 
~l.cx=lefl dEldk!XbbOdilOW. 
(Varian AA375, Sugarland, Texas) using 1.0% LaClj producing a partial constriction of the vessel. The ligature 
(final concentration = 0.5%) to suppress phosphate inter- was adjusted to reduce by at least 50% the reactive hyper- 
ference. Ion contents were expressed per gram of dry emit response to a lo-second occlusion of the left circum- 
tissue. No attempt was made to measure and correct for flex coronary artery without altering basal coronary 
the extracellular space because reperfusion after isch- blood flow. The method of producing the critical stenosis 
emia can cause gross changes in sarcolemmal permeabili- effectively reduces the incidence of hemorrhagic infarc 
ty? tion and lethal reperfusion arrhythmias.*l 
Studksonlimitatbnofultimateinfarctsizeinthein 
rstu canine heart- preparatbnr Detailed meth- 
ods have previously been published.17,21p22 Male mongrel 
dogs, selected with respect to breed and weighing be- 
tween 12 and 18 kg, were anesthetized with sodium pen- 
tobarbital (30 mg/kg i.v.). The dogs were ventilated with 
room air, delivered through a cuffed endotracheal tube, 
using a Harvard respiratory pump. Tidal volume and 
respiratory rate were adjusted to maintain arterial blood 
pH, pGz and pCO2 within physiologic limits. A thoracot- 
omy through the left fifth intercostal space was per- 
formed and the heart was suspended in a pericardial 
cradle. Catheters, placed in the external jugular vein and 
carotid artery, were used for the administration of drugs 
and monitoring arterial blood pressure, respectively. 
Leads II, III and aVF of the electrocardiogram were 
monitored continuously in all experiments. The left cir- 
cumflex coronary artery was isolated beneath the left 
atria1 appendage, distal to its atria1 branch and proximal 
to major ventricular branches. An electromagnetic flow 
probe connected to a digital readout meter (Carolina 
Instruments; King, North Carolina) was placed around 
the left circumflex coronary artery for continuous mea- 
surement of coronary blood flow. 
After reestablishment of a stable hemodynamic con- 
dition, the left circumflex coronary artery was occluded 
for 90 minutes using a reversible ligature made with 
Silastic tubing. After 90 minutes of regional ischemia, the 
occlusive snare was released over a period of 30 minutes, 
with the critical stenosis remaining in place. Leads II, III 
and aVF of the electrocardiogram, blood pressure and 
coronary artery blood flow were monitored and recorded 
on a Grass model 7 polygraph throughout the experimen- 
tal procedure. The experiments were completed after 6 
hours of reperfusion, after which the heart was arrested 
by electrically induced ventricular fibrillation and infarct 
size was assessed. The experimental protocol is presented 
in Figure 2. 
Approximately 15 minutes was allowed to establish a 
stable hemodynamic state, after which baseline measure- 
ments of heart rate, carotid arterial blood pressure and 
left circumflex coronary artery blood flow were recorded. 
After measurements of basal coronary blood flow, a criti- 
cal stenosis of the coronary artery was produced by plac- 
ing an 18- or 19-gauge needle alongside the exposed ar- 
tery, tying a short length of silk suture around the artery 
and needle, and quickly removing the needle, thereby 
Exeh&m and indurion criteria: Predetermined ex- 
clusion criteria were: (1) the presence of heart worms on 
final examination of the heart, (2) the failure to manifest 
discoloration (cyanosis) of the epicardial surface in the 
region of distribution of the left circumflex coronary ar- 
tery after occlusion, (3) a failure to exhibit electrocardio- 
graphic signs of ischemia (ST-segment elevation) in leads 
II, III or aVF of the electrocardiogram, (4) a failure to 
develop arrhythmias on reperfusion and (5) intractable 
ventricular fibrillation requiring more than 3 attempts at 
cardioversion using low direct-current pulses (20 J) ap 
plied directly to the surface of the heart. Antiarrhythmic 
drugs for the prevention of ventricular fibrillation were 
not used in these experiments because of recent reports 
suggesting that agents such as lidocaine reduce infarct 
size.26 
Adminkfra~ of amlodlpine and salims The dogs 
were assigned randomly to receive either amlodipine (150 
pg/kg, dissolved in 20 ml of 0.9% solution of sodium 
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chloride) or 0.9% sodium chloride solution (20 ml). 
Treatments were administered over a period of 5 minutes 
and were given 15 minutes before the onset of reperfusion 
(75 minutes after initiation of regional myocardial isch- 
emia) . 
Determination of myocardial infarct size and area at 
riskr The dogs were killed 6 hours after reperfusion by the 
electrical induction of ventricular fibrillation (60 Hz, 5 V, 
1-ms pulse duration applied to the surface of the heart). 
The hearts were excised and rinsed with warm 0.9% sodi- 
um chloride solution, weighed and attached to a perfusion 
apparatus. Histochemical determination of the anatomic 
area at risk and the zone of infarction was accomplished 
with an ex vivo dual perfusion technique.21J2,27 The left 
circumflex coronary artery was cannulated at the point of 
previous occlusion and perfused with 4% triphenyl tetra- 
zolium chloride (TX) in 20-mM potassium phosphate 
buffer (pH 7.4, 37’C), while the aorta was perfused 
retrogradely with 0.25% Evans blue dye. The solutions 
were infused simultaneously for 5 minutes under a con- 
stant pressure of 100 mm Hg with the heart suspended in 
a water bath (37’C). Differential perfusion of the cir- 
cumflex artery and remaining vasculature under these 
conditions delineates the anatomic area at risk, as well as 
infarcted myocardium, based on the ability of dehydroge- 
nase enzymes present in viable myocardium to react with 
TTC. With this histochemical technique, myocardium 
that is not part of the area at risk is stained dark blue. 
Within the boundaries of the area at risk, normal tissue is 
colored brick red by the formazan precipitate resulting 
from enzymatic reduction of TTC, while infarcted myo- 
cardium appears pale yellow. The heart was cut trans- 
versely into l-cm-thick sections, revealing 3 clearly de- 
fined areas (normal myocardium in the nonrisk region, 
normal myocardium in the risk region and infarcted myo- 
cardium in the risk region) of the left ventricle as defined 
by the histochemical procedure. The fidelity of the TTC 
staining method has been confirmed previously.28v29 After 
weighing each left ventricular section, the outline of the 3 
areas of both sides of each section were traced onto clear 
plastic overlays for subsequent quantification of the area 
at risk and the infarcted zone by planimetry using an 
Apple Graphics Tablet and Apple IIe computer. A cus- 
tom-made software program was used to calculate the 
masses of the infarct zone and the area at risk from the 
planimetered areas and the weights of each section. Previ- 
ous studies demonstrated that there is an excellent corre- 
lation between infarct size derived by the planimetric 
method and the direct gravimetric measurement.22 The 
method for the determination of myocardial infarct size is 
illustrated in Figure 3. The infarcted mass is expressed as 
a percent of the area at risk, and the area at risk is 
expressed as a percent of the left ventricle. 
Tissua calcium content measurementsr Portions of 
myocardial tissue, dissected from the 3 areas of the left 
ventricle (normal myocardium in the nonrisk region, nor- 
mal myocardium in the risk region and infarcted myoear- 
dium in the risk region), were oven-dried to constant 
weight and digested in nitric acid. The tissue Ca2+ con- 
tent of acid digests, diluted in lanthanum (LaCls; final 
NZ - NORMAL ZONE 
I2 I ISCHEMIC ZONE 
AR I AREA AT RISK 
Iz = Infarct Zone as a percent 
LV of the Total Left Ventricle 
Iz= infarct Zone as a percent 
AR of the Area at Risk 
A= Area at Risk as a percent 
LV of the Total Left Ventricle 
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concentration = 0.5%), was measured by atomic absorp 
tion spectrophotometry (Varian AA375, Sugarland, Tex- 
as). Serial dilutions of CaCOs standard solution, contain- 
ing identical amounts of nitric acid and LaCls, were used 
to construct a standard curve. 
Statistical analysis: All data are reported as mean f 
1 .O standard error of the mean. Differences between the 
mean values of treated and untreated groups were com- 
pared using Student r test for unpaired data. Differences 
between values within groups were tested for statistical 
significance using the paired t test. Differences at the p 
<0.05 level were considered statistically significant. Mul- 
tiple comparison analysis involving more than 2 groups 
were performed with analysis of variance. 
RESULTS 
Effectsofambdipineonghhalischemia-reperfusion 
injury in blood-pe&use~I feline i$oIatd heart: In all, 42 
cats (21 donor cats and 21 cats for isolated hearts) in 21 
experiments were used for this series of the study. Three 
experiments (6 cats) were excluded because of an inabili- 
ty to maintain stable hemodynamic conditions associated 
with metabolic acidosis of the donor cats. Thus, 36 cats 
(18 donor cats and 18 cats for isolated hearts) in 18 
experiments initially entered the protocol. The study 
groups consisted of 11 control (placebo-treated) and 7 
amlodipine-treated hearts. 
Changes In arterial blood pressure in donor cats af- 
ter administration of amlodipine: The changes in systol- 
ic, diastolic and mean arterial blood pressure in the blood 
donor cats after amlcdipine or sodium chloride infusion 
are shown in Figure 4. Systolic blood pressure decreased 
from125f14to115f12mmHg(p<0.05)20minutes 
after the intravenous administration of amlodipine to the 
blood donor cat. The administration of the diluent to the 
control group was not associated with any change in the 
blood pressure of the blood donor cat. 
Effects of amlodiptne on nonischemic, blood-per- 
fuse!d felim heart: The changes in left ventricular con- 
tractile function, MV02 and coronary blood flow after 
infusion with amlodipine or placebo are listed in Table I. 
The rate of the perfusion pump providing flow to the 
coronary arteries of the isolated hearts was not changed 
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until measurements after administration of the drug or 
placebo were obtained. Amlodipine exerted a negative 
inotropic effect and caused a commensurate decline of 
MV02 (and rate-pressure product). The intrinsic heart 
rate decreased, but not significantly. Coronary vascular 
resistance decreased, necessitating an increase in the out- 
put of the coronary artery perfusion pump so as to return 
the coronary perfusion pressure to the predrug value. The 
increase in coronary blood flow was 8% (1.07 f 0.05 to 
1.16 f 0.10 ml/mm/g) greater than that of the control 
flow before the administration of amlodipine. The change 
in coronary resistance, however, did not differ significant- 
ly from control. 
Administration of amlodipine was associated with sig- 
nificant decreases in LVDP ( 120 f 1 to 100 f 4 mm Hg), 
which was reflected in a decrease in MV02 (6.2 f 0.4 to 
4.4 f 0.4 ml O&nin/lOO g) as well as a decrease in left 
ventricular dP/dtmax and rate-pressure product. Thus, 
amlodipine (150 pg/kg) administered to the blood donor 
cat produced a negative inotropic effect in the blood- 
perfused isolated heart, which reflects an overall decrease 
in myocardial contractile function and a subsequent re- 
duction in MV02. The data for each of the recorded and 
derived parameters are presented in Table I. 
Resting ledl wntriab presswe changes during 
global itschemii: The interruption of coronary perfusion 
and the induction of global myocardial ischemia induced 
a rapid decline in LVDP. During the period of ischemic 
arrest, the resting left ventricular pressure (which would 
correspond to left ventricular diastolic pressure in the 
beating heart) began to increase progressively starting 20 
minutes after the onset of global ischemia. After 60 min- 
utes of global ischemic arrest, the resting left ventricular 
pressure had increased from an initial preset value of 15 
mm Hg to a mean value of 77 f 8 mm Hg in the saline- 
treated hearts. In contrast, amlodipine pretreatment 
slowed the time course of the rate of increase of resting 
left ventricular diastolic pressure, and at the end of 60 
minutes the resting left ventricular diastolic pressure was 
33 f 6 mm Hg (p <0.05). Data are summarized in 
Figure 5. 
Therefore, amlodipine administered before the onset 
of global ischemia significantly decreased the extent of 
development of ischemic contracture as reflected in a 
progressive increase in the resting LVEDP at each time 
point between 20 and 60 minutes of global ischemic arrest 
of the feline isolated heart. 
EIe&kaI ac&ityr At the onset of ischemia, there was 
a rapid dissociation between contractile and electrical 
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+ Amlodipine (n=6) 
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lwefthemeen. 
velopment ceased within 60 seconds after termination of ed hearts are shown in Figures 7 and 8. Sixty minutes of 
coronary artery perfusion, electrical activity continued global ischemia plus reperfusion resulted in a decrease in 
for several minutes. Heart rate slowed gradually and LVDP compared with the preischemic control values in 
changed from a sinoatrial rhythm to one which was ven- the salinetreated group (LVDP, -43.5 f 1.3% of pre- 
tricular in origin. Ventricular fibrillation did not occur in ischemic value). Pretreatment with amlodipine attenuat- 
any heart during the ischemic period, but all hearts fibril- ed the deterioration in ventricular performance on reper- 
lated immediately on reperfusion. In the saline-treated fusion at each point on the left ventricular function 
group of hearts, 6 of 11 hearts reverted spontaneously to curves. Amlodipinetreated hearts showed less of a de- 
sinus rhythm, while 6 of 7 amlodipine-treated hearts cline in LVDP (-20.5 f O.%) as a result of 60 minutes 
spontaneously returned to normal sinus rhythm after re- of ischemia and reperfusion (Fig. 7). Amlodipine also 
perfusion. The percentage of recovery was greater in am- attenuated the decrease in left ventricular dP/dtmax 
lodipine-treated hearts, although the difference between compared with saline-treated ischemic hearts (Fig. 8). As 
the 2 groups with respect to the spontaneous return to noted previously with respect to ventricular function, am- 
normal sinus rhythm was not statistically significant lodipine, despite its own intrinsic negative inotropic ef- 
(54.5% in the saline-treated group, 85.7% in the amlodi- fect, provides protection against the depression in myo- 
pine-treated group [difference not significant; p = NS] cardial contractility that results in the control hearts after 
by Fisher exact test). a period of global ischemia followed by reperfusion. 
lsclwda/reparhuSeni dmnges et left ven- Coronaq bbod flew: The values obtained for the 
triuder eontraetile issue&r and eomp&aneer Changes in measurements of coronary blood flow, before and after 
left ventricular compliance resulting from 60 minutes of &hernia reperfusion, are shown in Figure 9. Coronary 
ischemia followed by 60 minutes of reperfusion are shown blood flow was measured while the hearts were paced 
in Figure 6. There was no difference between the 2 groups electrically at a rate of 150 beats/mm, with LVEDP set 
in the weight of the isolated hearts (saline-treated group at 0 mm Hg. The values for coronary blood flow were 
= 12.0 f 0.7 g, amlodipine-treated group = 12.6 f 0.7 g; normalized for heart weight and expressed in ml/mm/g 
p = NS). There was a significant decrease in compliance weight. Isolated hearts had a mean preischemic coronary 
(preischemic vs l-hour reperfusion) in both the saline- blood flow of 1.20 f 0.05 ml/min/g for the control group 
and amlodipinstreated groups after ischemia and reper- and 1 .lO f 0.07 ml/mm/g for the amlodipine group (p = 
fusion. In the saline-treated group, all values were shifted NS). Coronary blood flow increased to 1.67 f 0.20 ml/ 
to the left, compared with the corresponding points on the min/g (+30% of preischemic value) after 60 minutes of 
preischemic curve indicating a decrease in left ventricular ischemia followed by 60 minutes of reperfusion in the 
compliance. The amlodipinstreated group also was char- saline-treated hearts (p = 0.021). In the amlodipine- 
acterized by a leftward shift in the ventricular compliance treated group there was a further decrease in coronary 
curve, but of a lesser magnitude at each value of left vascular resistance so that coronary blood flow was 2.5 f 
ventricular volume compared with the changes observed 0.33 ml/min/g (+127%) after &hernia plus reperfusion. 
in the saline-treated control group. Amlodipine pretreat- Although there was a marked increase in coronary flow in 
ment resulted in a significant shift in the ventricular com- amlodipine-treated hearts, when compared with the sa- 
pliance curve toward the right compared with changes in line-treated group, the overall increase did not achieve 
the saline-treated group. statistical significance (p = 0.057; unpaired t test). 
Ventricular function curves for the 2 groups of isolat- Tissue amxlysis~ Values for water and electrolyte con- 
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tents in myocardial tissue are presented in Table II. The 
hearts from blood donor cats served as nonischemic con- 
trols. Previous studies from this laboratory20>3? demon- 
strated that the isolated blood-perfused, nonischemic 
control hearts did not differ from the hearts of the blood 
donor cats with respect to tissue contents of water, sodi- 
um, potassium or calcium. The bloodhperfused isolated 
heart maintains its ability to control water and electrolyte 
composition. Any changes in water and electrolyte corn; 
position of the isolated heart could be attributed directly 
to the applied interventions and not to the fact that the 
heart had been isolated and perfused for an extended 
period. In both the saline- and amlodipine-treated isch- 
emic/reperfused hearts there was a significant increase in 
water content, indicating edema formation. The differ- 
ence between the 2 groups was not significant. Tissue 
potassium content decreased in both groups of ischemic 
hearts compared with normal hearts from the blood do- 
nor cats. Treatment with amlodipine attenuated the loss 
of potassium. Tissue calcium content increased in both 
groups as a result of ischemia plus reperfusion, and the 
calcium content in amlodipinstreated ischemic hearts 
was less than that in the saline-treated hearts. Thus, from 
the standpoint of electrolyte composition of the reper- 
fused heart, amlodipine resulted in significant reductions 
in the loss of intracellular potassium and reduced the 
amount of calcium that accumulated during the period of 
reperfusion. The latter observation would be consistent 
with the finding that amlodipine preserved both systolic 
and diastolic functions of the reperfused heart. 
Effects of ambdipine on extent of ultimate infarct 
~~m--w-Ycoronary ecchdsienand 
rape&&~ in canine M In all, 27 dogs (13 amlodi- 
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Cat isolated blood-perfused heart 
pine- and 14 salinetreated dogs) were used in this series 
of experiments. Four dogs (2 amlodipine- and 2 saline 
treated dogs) were excluded before the initiation of amlo- 
dipine or saline infusion because of failure to manifest 
any objective evidence of regional myocardial ischemia 
on left circumflex coronary artery occlusion. Two dogs (1 
amlodipina and 1 salinetreated dog) were excluded be- 
cause more than 3 attempts at cardioversion were re- 
quired to reverse ventricular fibrillation. One dog (saline 
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TABLE II Myocardial Water and Electrolyte Content 
Water 











Donor heart (n = 6) 3.5*0.1+ 18.3 f 1.2+ 
Ischemia-repetfused (n = 6) 5.7 f 0.1 43.9 f 1.6 
Amlodipine-treated group 
Donor heart (n = 6) 3.3*0.1+ 19.4 f 2.4+ 
Ischemia-reperfused (n = 6) 5.5 f 0.3 36.6 f 2.6* 
* Sodium concentrations were corrected for sodium accumulation due to edema (for calculations. see Methods.) 
7 p SO.05 donor heart M ikchemia-reperfused heart. 
* p <0.05: saline-treated group w amlodipiwtreated group. 
Values are mean f standard error of the mean. 
32.6 f 1.7+ 7.3 f 1.2+ 
20.5 f 0.7 21.3 f 2.0 
33.8 f 1.8+ 6.9 f 0.9+ 
25.7 f 2.6* 15.7 f 1.8* 
treated) died of intractable ventricular fibrillation during 
reperfusion and was not included in the final analysis of 
the data with respect to infarct size. Thus, the final 
groups consisted of 10 amlodipine- and 10 saline-treated 
dogs. 
Group ehsuaete&tksr Body weight: Comparison of 
the 2 groups of animals with respect to body weight failed 
to demonstrate a significant difference between the 2 
groups (15.7 f 0.3 vs 16.1 f 0.4 kg for saline vs amlodi- 
pine groups). 
Heart size: Total heart weight was the same for both 
groups (136.3 f 6.6 vs 140.2 f 6.8 g for saline vs amlodi- 
pine groups). Total left ventricular weight was similar in 
both groups (94.9 f 5.8 vs 101.6 f 4.1 g for saline vs 
amlodipine groups). 
Effecl of ambfBpine aa btthate myacadal infarct 
size: Infarct size analysis is presented in Figure 10. In- 
farct size expressed as a percent of the anatomic area at 
risk in the amlodipine-treated group was smaller than 
that in the salinetreated group (45.9 f 2.8 vs 34.5 f 
3.8% for saline vs amlodipine groups; p 10.025). There 
was a significant difference in infarct size when the data 
are expressed as a percent of the left ventricle (18.6 f 1.5 
vs 13.6 f 1.6% for saline vs amlodipine groups; p <0.05). 
The ratio of the area at risk of becoming infarcted com- 
pared with the area of the left ventricle did not differ 
between groups (40.5 f 1.8% vs 40.2 f 1.3% for saline vs 
amlodipine). Assessment of infarct size as a percentage of 
the area at risk demonstrated that treatment with amlodi- 
pine produced a 24.8% reduction in ultimate infarct size. 
Area at risk: The area at risk (determined with the Hemodynamic par- Preocclusion values of 
dual perfusion method using Evans blue and triphenyl- heart rate, mean arterial blood pressure, rate-pressure 
tetrazolium), expressed as a percent of the left ventricle, product and mean left circumflex coronary blood flow 
did not differ between the 2 groups (40.5 f 1.8 vs 40.2 f were similar in the 2 groups (Table III). There were no 
1.3% for saline vs amlodipine groups). Overall area at risk significant intergroup differences in these parameters 
for 20 experimental dogs was 40.2 f 4.9% of the total left during 90 minutes of coronary artery occlusion and 6 
ventricle. Because the small variability in the size of the hours of reperfusion. Mean arterial blood pressure 30 
risk region, the dependence of infarct size on the area at minutes after reperfusion significantly decreased com- 
risk size was eliminated as a variable, therefore making it pared with preischemic control values in the amlodipine- 
possible to assess the potential of a pharmacologic agent treated group. Mean coronary blood flow between 3 and 
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(Saline vs. Amlodipine) 
Non-Ischemic Non-Infarcted Region 
Region within Area at Risk 
Center of 
Infarcted Zone 
lower than the preischemic values. Heart rate between 5 
and 6 hours after reperfusion in the saline-treated group 
and between 4 and 6 hours after reperfusion in the amlo- 
dipine-treated group was increased compared with pre- 
ischemic control values in each group. However, there 
were no significant between-group differences over the 
time course of the protocol. In addition, there were no 
significant intergroup differences in ratepressure prod- 
uct after the infusion of saline or amlodipine. 
Tlssw e&hmn m The Ca*+ content of myocar- 
dial tissues is presented in Figure 11. In both groups, the 
Ca*+ content of noninfarcted and infarcted tissue within 
the area at risk, was greater than myocardial tissue ob- 
tained from the nonischemic region, the content being 
greater in the central infarcted zone. Amlodipine signifi- 
cantly attenuated the elevation of tissue Ca*+ in the non- 
infarcted myocardium within the area at risk. Tissue 
Ca*+ content in the infarcted zone tended to be lower in 
the amlodipine-treated group, but the difference was not 
statistically significant. 
DISCUSSION 
The experimental results indicate that administration 
of the new dihydropyridine derivative amlodipine before 
the onset of global ischemia is effective in preserving 
myocardial function in the isolated, blood-perfused feline 
heart. Investigators using diltiazem,3O nifedipine3i and 
verapamiP* have shown that these agents offer protection 
in similar settings of myocardial injury. Similarly, amlo- 
dipine was shown to decrease the extent of myocardial 
necrosis when given 15 minutes before reperfusion in the 
intact canine heart which was subjected to 90 minutes of 
regional ischemia. Administration of Ca*+ channel entry 
blockers before the onset of ischemia has been shown to 
reduce infarct size in models of permanent occlusion and 
ischemia followed by reperfusion.8J7J9 To better under- 
stand the role of Ca*+ channel blockade in preventing, 
rather than delaying, irreversible injury during reperfu- 
sion, we gave amlodipine before the onset of reperfusion. 
The observed reduction in infarct size may be attribut- 
able, in part, to the prolonged duration of action of this 
agent.5 
The importance of ischemia and reperfusion in the 
etiology of myocardial cell injury has been reviewed ex- 
tensively.33v34 Corresponding with the onset of ischemia is 
an abrupt cessation of oxidative phosphorylation in the 
mitochondria due to the decreased 02 tension. Anaerobic 
glycolysis is accelerated initially, but eventually declines 
despite the persistence of endogenous glycogen stores.35 
As the ischemic interval lengthens, all pathways for the 
generation of ATP are inhibited, leading to very low 
concentrations of intracellular ATF’.36 Because many of 
the homeostatic mechanisms are energy dependent, regu- 
lation of tissue electrolyte composition is abnormal in this 
setting. Early studies performed in the dog demonstrate 
that during ischemia, total cellular Ca*+ concentration 
does not change,37 but on the reintroduction of calcium 
containing perfusion medium, intracellular Ca*+ in- 
creases significantly. The increase in intracellular Ca*+ 
during reperfusion is due to an increase in Ca*+ influx.38 
The reactivation of oxidative phosphorylation, known to 
occur during reperfusion, may be involved in the active 
uptake of Ca2+.39 Steenbergen et al‘@ showed that intra- 
celhtlar free Ca*+ also increases during ischemia, al- 
though at a slower rate, presumably through the release 
of intracellular Ca*+ stores. The observed changes in 
Ca*+ and its regulation are thought to be involved in the 
cellular damage observed in ischemia and reperfusion. 
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In this study, we use 2 different experimental models 
in order to assess the possible therapeutic role of amlodi- 
pine in the setting of acute myocardial ischemia and 
reperfirsion. Because of the intrinsic nature of Ca*+ chan- 
nel entry blockers to relax vascular smooth muscle, the 
isolated, blood-perfused feline hearts were chosen in or- 
der to eliminate the possibility of modified cardiac perfor- 
mance, which might have occurred as a result of de- 
creased afterload or variations in regional myocardial 
blood flow, or both. One of the particular advantages 
offered by this model is the absolute assurance of global 
ischemia. Other investigations using various Ca*+ chan- 
nel entry blockers and other vasodilators have often re 
ferred to “coronary steal” as a possible mechanism, which 
may account for a possible deleterious effect of these 
agents.41 This phenomenon, however, cannot exist in tis- 
sues that are made globally ischemic. In addition to the 
exclusion of hemodynamic variability, the isolated heart 
offers the advantage of procuring measurements indepen- 
dent of alterations in central nervous system input to the 
heart. Previous studies have used this mode120+30 of global 
ischemia (60 to 90 minutes) followed by reperfusion (1 to 
2 hours) for the assessment of contractile function, elec- 
trophysiologic parameters and coronary vascular resis- 
tance. We used the isolated heart model as part of a 
rational protocol designed to assess the effects of amlodi- 
pine on myocardiil performance and electrolyte balance 
in the absence of hemodynamic and central nervous sys- 
tem variations. 
The susceptibility of the canine heart to myocardial 
ischemia has been compared with other species, and it has 
been shown that reproducible regional myocardial necro- 
sis can be achieved after temporary coronary occlusion 
followed by reperfusion.*7*21p22 The intact canine heart, 
unlike the isolated heart protocol, assesses drug responses 
in an intact physiologic system in which hemodynamic 
and central nervous system responses are not maintained 
under artifical control. As a result, drug-related changes 
in systemic arterial blood pressure, heart rate, coronary 
blood flow and MVO2 can be monitored. The intact ca- 
nine heart was used to assess the efficacy of amlodipine in 
reducing that component of myocardial necrosis, which 
can be attributed to the late stage of &hernia and reper- 
fusion when the drug is administered 15 minutes before 
the restoration of regional myocardial perfusion. 
Results from isolated, btood-pedused feline hear& 
Amlodipine evoked hemodynamic alterations typical of 
the diiydropyridine class of Ca*+ channel entry blockers 
in the setting of global ischemia and reperfusion. Amlodi- 
pine given before the onset of ischemia increased coro- 
nary blood flow in the isolated heart and decreased mean 
arterial blood pressure in the blood donor cat. The ob- 
served actions of amlodipine may be due to the inhibition 
of the slow inward Ca*+ current. The dihydropyridines 
are considered to function by binding to specific sites 
directly within the ion channel.42 The binding selectivity 
of the dihydropyridines may confer an undetermined ac- 
tion independent of ion flux.43 During ischemia there is a 
gradual increase in [Ca*+]i that is thought to be secon- 
dary to the metabolic breakdown of energy-producing 
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systems leading to an inhibition of the ATP-dependent 
homeostatic control mechanisms4 Pretreating isolated 
hearts with calcium channel entry blockers has demon- 
strated a mechanical and biochemical protection during 
prolonged ischemia.45-47 
However, experiments performed on isolated myo- 
cytes pretreated with specific and nonspecific calcium 
channel entry blockers (nifedipine and diltiazem; lidofla- 
zine and flunarizine, respectively) failed to prevent hyper- 
contracture with nifedipine and diltiazem, but did protect 
in the presence of the nonspecific agents lidoflazine and 
flunarizine.48 These results indicate a possible intracellu- 
lar action of Ca*+ regulation. Recently, Sperelakis et a149 
suggested that the increase in [Ca*+]i during ischemia 
may be due to a failure of the metabolic processes to 
pump free Ca*+ out of the cell. Similarly, Dhalla et a150 
showed an inhibition of sarcoplasmic reticular Ca*+ 
ATPase uptake and Na+/Ca*+ exchange mechanisms 
during anoxia and ischemia. Because Ca*+ probably en- 
ters by more than 1 route during reperfusion, specific 
Ca*+ channel entry blockers, while effective during isch- 
emia, can only delay but not abolish the reperfusion- 
induced gain in Ca*+ that is associated with cell death. 
Tissue electrolyte analysis showed that amlodipine 
was able to inhibit the changes in myocardial electrolyte 
concentrations due to ischemia/reperfusion. Global isch- 
emia followed by reperfusion was associated with an in- 
crease in myocardial Ca*+ and Na+, and a loss in tissue 
K+. These results are consistent with previous studies that 
describe alterations in electrolyte homeostasis during 
ischemia/reperfusion. 37~51 In comparison with control 
hearts, amlodipine pretreatment substantially reduced 
the relative increase in [Ca*+]i and [Na+]i, and reduced 
the 10~s of [K+]i associated with ischemia. Because the 
samples were obtained after 1 hour of reperfusion, Ca*+ 
measurements do not reflect changes in [Ca*+]i resulting 
from ischemia. During prolonged ischemia (>20 min- 
utes) [Ca*+]i increased, but total cellular Ca*+ remained 
constant; this subtlety reflects intracellular functional de- 
rangements in the mitochondria and sarcoplasmic reticu- 
lum. Nayler et al’* performed ultrastructural analysis of 
the sarcolemmal membrane after 60 minutes of ischemia 
and found it to be largely intact. The observed increase in 
[Ca*+]i in our experimental model is consistent with the 
rapid influx of Ca*+ that occurs on reperfusion. Reperfu- 
sion-associated increases in [Ca*+]i caMot occur through 
activation of the slow channels alone.52 It has been postu- 
lated that the gradual loss of membrane integrity occurs 
during ischemia by various mechanisms including: acti- 
vation of phospholipases,53 accumulation of lipids,54 Or 
free radicals55 or other undefined mechanisms, thus re- 
moving the physical barriers allowing the free diffusion of 
Ca*+ down its concentration gradient that occurs at 
reperfusion. Therefore, the relative decrease in total 
[Ca*+]i after amlodipine pretreatment may be due to an 
inhibitory action on those events that lead to the initiation 
of membrane damage during the ischemic period; the 
metabolic and structural alterations that normally serve 
as the substrate for reperfusion injury-Ca*+ overload- 
are eliminated. By pretreating the globally ischemic/re 
perfused heart, we did not define the role of the Ca*+ 
channel blockers in reperfusion injury. 
During ischemia there was a rapid decline in devel- 
oped tension and a progressive increase in LVEDP begin- 
ning between 10 and 20 minutes after cessation of flow. 
Although we did not obtain tissue Ca*+ measurements 
throughout the ischemic interval, the progressive increase 
in LVEDP has previously been shown to be associated 
with a steady increase in free [Ca2+]i.56 The increased 
[Ca*+]i may be due to an inability of myocytes to remove 
free Ca*+ from the cytoplasmic space through an inhibi- 
tion of the active reuptake systems of the sarcoplasmic 
reticulum, mitochondria, and sarcolemmal membrane.49 
Previous studies have shown that the increase of [Ca2+]i 
that occurs during anoxia and ischemia is not due to an 
influx of extracellular Ca*+, but is related to alterations in 
Ca*+ extrusion and sequestration.50J6 The redistribution 
of [Ca*+]i into usable free Ca*+ inhibits mitochondrial 
oxidative phosphorylation by diverting energy production 
to the active sequestration of Ca*+ in the mitochondria.50 
Amlodipine inhibited the increase in LVEDP throughout 
the 60-minute period of ischemia. By inhibiting the onset 
of myocyte hypercontracture, amlodipine may prevent 
the further mechanical disruption and chemical degrada- 
tion of an already compromised sarcolemmal membrane, 
thereby making the cells less susceptible to Ca*+ overload 
on reperfusion. This action of amlodipine and the other 
calcium channel entry blockers, when given before the 
onset of ischemia, is similar to the energy-sparing drugsS7 
and high-energy phosphate precursors.58*59 Amlodipine, 
in addition to its action on the slow calcium channel, may 
function by a mechanism, as yet to be described, involving 
the intracellular regulation of Ca*+ release from the sar- 
coplasmic reticulum. 
Two indexes of myocardial function were used to as- 
sess the physiologic effects of amlodipine (compliance 
and function). Amlodipine improved functional recovery 
on reperfusion, but did not afford a complete return to 
baseline conditions. These results suggest that amlodipine 
exerts a protective effect during ischemia/anoxia, but on 
reperfusion, a degree of protection is lost. Reperfusion 
injury is a complex and multifactorial event.33s44 The 
common final denominator, however, appears to be the 
rapid influx of Ca*+ concomitant with the reintroduction 
of molecular 02 and metabolic substrates. The “calcium 
paradox” or calcium overload can occur even in the ab- 
sence of 02; intracellular accumulation of 02 radicals 
during ischemia may be sufficient to cause cell damage, 
thus allowing for rapid Ca*+ influx.52,55 Calcium can 
enter the damaged myocyte through a variety of different 
pathways including Na+-Ca*+ exchange, diffusion 
through damaged membrane, ion-channels and release 
from intracellular stores. It has been shown that amlodi- 
pine and the related dihydropyridines can prevent Ca*+ 
influx through the ion channel. Other pathways for Ca*+ 
entry undoubtedly remain functional, thus preventing full 
recovery of function despite previous administration of 
amlodipine.52 Closely related to the recovery of contrac- 
tile function is the fact that amlodipine reduced MV02 
(arteriovenous difference). Coronary blood flow was im- 
proved, an event that may have been due to a direct action 
on the vascular smooth muscle. Alternatively, because 
coronary blood flow is impeded by extravascular com- 
pression, prevention or reduction in the development of 
contracture during ischemia and especially on reperfu- 
sion would result in an improved distribution of blood 
flow to the myocardium, which would not necessarily be 
reflected in an overall increase in total coronary blood 
flow. Furthermore, the no-reflow phenomenon may have 
been prevented by amlodipine, thus facilitating better 
perfusion of the tissue on the restoration of coronary flow. 
Our experimental design did not enable us to differentiate 
whether improved performance was due to decreased 
MVOz or an improved tissue distribution of coronary 
flow. 
Results from intact canine hear& Previous studies 
have shown that Ca*+ channel entry blockers are effec- 
tive in reducing infarct size and improving cardiac func- 
tion when administered before the onset of coronary ar- 
tery occlusion in intact animal preparations.17T60 Possible 
cardioprotective mechanisms have been described and 
include increased regional myocardial blood flow, de- 
creased afterload through systemic arteriolar dilation, 
decreased MV02, decreased heart rate and direct nega- 
tive inotropic effects. Direct inhibition of neutrophil acti- 
vation may also play a beneficial role in reducing the 
ultimate extent of damage.61*62 In contrast, calcium chan- 
nel entry blockers are ineffective when administered con- 
comitantly with reperfusion.43 Intervention with low 
Ca*+ containing solutions or acidic reperfusate can delay, 
but not prevent, the expression of cellular damage.52 
Convincing evidence has shown that much of the 
damage associated with reperfusion occurs within min- 
utes of the restoration of flo~.*~ Shen and Jennings3’ 
showed that total cellular Ca*+ was unchanged during 
ischemia, but increased abruptly on reperfusion. The fail- 
ure of calcium channel entry blockers to improve cardiac 
function and reduce infarct size when given during reper- 
fusion alone is likely due to the rapid loss of sarcolemmal 
membrane integrity associated with restoration of flow 
and subsequent loss of homeostatic mechanisms. Isch- 
emia primes the cells for destruction through activation 
of proteases, 02-free radicals and calcium ATPases.13v50 
Gross disruption of the sarcolemma develops in associa- 
tion with reperfusion and such perturbations are not evi- 
dent during ischemia alone, despite the fact that the cell 
membrane has been altered with respect to its permeabili- 
ty characteristics.52~63~64 As a result, Ca*+ moves unim- 
peded into the cytoplasmic space during reperfusion. 
Ca*+ influx may be one of the final common pathways 
that result in myocardial dysfunction and necrosis. 
In deference to its relatively prolonged onset of action, 
we administered amlodipine 15 minutes before the onset 
of reperfusion. In contrast to other studies in which Ca*+ 
antagonists given at the time of reperfusion demonstrated 
no reduction in infarct size or improvement in myccardial 
function,38*43y65 amlodipine reduced infarct size and de- 
creased intracellular Ca*+ concentrations in the nonin- 
farcted tissue in the area at risk. In a study performed 
with the working rat heart, Higgins et a143 observed no 
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protective effect by verapamil or diltiazem when the 
drugs were administered at the time of reperfusion; nifed- 
ipine and the calmodulin antagonist W-7, however, were 
found to be beneficial when given at reperfusion or when 
given before ischemia. They concluded that Ca2+ antago- 
nists may act differentially on the sarcolemmal mem- 
brane. Furthermore, it was suggested that nifedipine may 
exert its protective effects by an intracellular action simi- 
lar to that attributed to W-7 on calmodulin.66 
Our data suggest that the observed reduction in myo- 
cardial infarct size was independent of altered hemody- 
namic parameters: heart rate, mean arterial blood pres- 
sure, coronary blood flow and the rate-pressure product 
that did not differ between treated and control animals. 
The possibility remains, however, that alterations in re- 
gional myocardial blood flow may have contributed to 
tissue salvage. Studies done in a canine model of severe 
ischemic injury showed that nifedipine reduced myocar- 
dial injury due to an increase in collateral blood flo~.~ 
Pretreatment with amlodipine 15 minutes before reperfu- 
sion may have attenuated late ischemic phase alterations 
in the homeostatic mechanisms. Nayler et a16’ showed 
that the duration of ischemia is directly proportional to a 
decrease in dihydropyridine receptor affinity (b) and 
receptor density (Bmax) for the low affinity slow calcium 
channel, thereby allowing increased binding of nifedipine 
during ischemia; such alterations have not been demon- 
strated during reperfusion. This increased binding may 
be associated with an increase in membrane stability. 
Data from Jennings et aP9 and Poole-Wilson et a165 sug- 
gest that Ca2+ antagonists may increase sarcolemmal 
membrane stability. By increasing membrane stability 
during ischemia, amlodipine may preserve the integrity of 
intracellular Ca2+ homeostatic mechanisms throughout 
reperfusion, allowing better extrusion of Ca2+ through 
the energy-dependent pumps, thereby attenuating Ca2+ 
overload and the resultant myocardial damage. Dhalla et 
also suggested that irreversible damage occurs on reperfu- 
sion when Ca2+ removal becomes defective. Our results 
indicate that amlodipine, although it did not completely 
inhibit the increase in [Ca2+]i in the noninfarcted tissue, 
it did attenuate the increase in myocardial [Ca2+]i com- 
pared with controls. 
It has become recognized that the excessive influx of 
Ca2+ associated with ischemia/reperfusion injury occurs 
almost exclusively during reperfusion; this increase can- 
not be due to increased conductance through the Ca2+ 
channel alone.38v43 By administering amlodipine 15 min- 
utes before reperfusion, we have demonstrated a reduc- 
tion of infarct size that has been typical of hearts treated 
before ischemia, but unlike those treated only during 
reperfusion. These results cannot be attributed to alter- 
ations in hemodynamic parameters. Although not deter- 
mined in the present study, the observed beneficial effect 
of amlodipine may have occurred as a result of improved 
distribution in regional blood flow to the reperfused myo- 
cardium. Prophylactic treatment with amlodipine during 
late ischemia may provide enough protection to keep the 
sarcolemma and tissue calcium homeostatic mechanisms 
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intact during reperfusion. Relative reductions in the ac- 
cumulation of [Ca2+]i compared with control suggest 
that amlodipine may exert a direct protective effect on 
the myocardium during ischemia, which may carry over 
into the reperfusion phase through membrane stabiliza- 
tion or, as suggested earlier, through an intracellular 
mechanism. Amlodipine may also reduce activation of 
leukocytes that would limit enzymatic and oxidative 
damage associated with ischemia and reperfusion in par- 
ticular.6*T62 
CONCLUSION 
The data suggest that the long-acting dihydropyridine 
derivative amlodipine is effective in preserving myocardi- 
al contractile function and reducing the extent of Ca2+ 
accumulation after 60 minutes of ischemia and reperfu- 
sion when administered before the onset of ischemia in an 
isolated, blood-perfused feline heart. We also demon- 
strated that amlodipine, given 15 minutes before the on- 
set of reperfusion after 75 minutes of regional ischemia, 
limits ultimate infarct size in the canine heart subjected 
to 90 minutes of ischemia and 6 hours of reperfusion. The 
observed protective effect was associated with a reduction 
in tissue Ca2+ accumulation in the noninfarcted region of 
the area at risk. Amlodipine may be useful as a cardiopro- 
tective agent providing preservation of cardiac function 
and cell viability during events that involve myocardial 
ischemia and reperfusion. 
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PANEL DISCUSSION 
Dr. Glossmann (h~nsbruck, Austria): I can try to an- 
swer 1 question and this is that you have 1,4-dihydropyri- 
dine and diltiazem which do the same thing. I can exclude 
the mitochondrial site which we work on. We can exclude 
the nucleotide carrier as a target for both the drugs, and I 
think we can also exclude the channel. So this leaves us 
with a fourth site, and I can say this because the vera- 
pamil group of drugs always goes together for all the 
receptors. If you study Escherichiu coli or mitochondria, 
all this goes together with the DHP receptor. We have 
not found yet, a receptor where the diltiazem-benzo- 
diazepine site goes together with the 1 &dihydropyridine 
site. 
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Dr. Nayler (Viioria, Australia): Do you have any 
information on what is happening to the cytoskeleton of 
the myocytes in your calcium antagonist treated model? 
Dr. l.ucdmi (Ann A&or, Mid&an): Yes, I have 
some very nice electron micrographs on this subject. 
There appears to be excellent preservation of the ultra- 
structure. 
Dr. Naylez Not just ultrastructure, but also the cyto- 
skeleton of the cell? 
Dr. Uecheai: No, I don’t have that kind of informa- 
tion. 
Dr. Naylee I think this is terribly important because 
we must stop the cell membrane from swelling, which 
means we have to keep it anchored. I wonder if the calci- 
um antagonist drugs have this effect? 
Dr. Luccheri: I can’t answer that. 
Dr. Naylec We agree with you the ultrastructure is 
marvelously preserved, but we are also looking now in 
detail at the q&skeleton of the cell. 
Dr. Lueehe& I might point out that I didn’t show the 
data, but in our mitochondrial studies, mitochondrial 
function is beautifully preserved. 
Dr. Vanhoutte (Rocheaer, Mimwsota): The story 
you tell us today and your story too, Dr. Nayler, reminds 
me very strongly of the stories on lidotlazine about 10 
years ago. Does that help in understanding why those 
drugs could act and what they could do? 
Dr. Uuheaiz I think lidoflazine is acting very much in 
the same way. 
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